Vendite dei farmaci per diabete di Novo Nordisk, tra cui Ozempic Slot Slotly: società danese per ridurre i costi e prendere in considerazione i licenziamenti dopo la concorrenza di Mounjaro e del mercato CopyCat

    https://www.theguardian.com/business/2025/aug/06/sales-of-novo-nordisk-diabetes-drugs-including-ozempic-slow-sharply

    di Ok_Plankton_5714

    Share.

    6 commenti

    1. Econ_Orc on

      NOVO has in the past 6 months delivered a 55 billion kroner profit (Danish record).

      It is still making money. A lot of money. It is just the expectations and predicted growth that did not meet reality.

    2. yellowbai on

      If they get the prices down they can ramp up volume. The prices are ridiculous for it. There is also approvals processes in motion from insurance companies to get it approved the same way statins are.

    3. Aware-Computer4550 on

      It’s a really competitive market for obesity meds

    4. punter112 on

      Patent for Ozempic expires next year. 
      Mounjaro is better for most purposes.
      It’s a tough spot for them.

    Leave A Reply